Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

Safety Study of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor in Subjects With Rheumatoid Arthritis [Phase 3b/4 Randomized Safety Endpoint Study of 2 Doses of Tofacitinib in Comparison to A Tumor Necrosis Factor (TNF) Inhibitor in Subjects with Rheumatoid Arthritis

Category & Conditions:
Immune System Diseases and Conditions
Medicine:
XELJANZ®(TOFACITINIB)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
A3921133
Open Plain Language Summary Result:Click here